Our data strengthen this hypothesis, in fact, in the CML context, EPAS1 down-regulation is involved in the escape from IM treatment of BCR-ABL-positve cells. The gene discussed is EPAS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.